Satu Mustjoki
AuthID: R-00F-ETA
1
TÃTULO: FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study
AUTORES: Mahon, Francois Xavier; Richter, Johan; Hochhaus, Andreas; Panayiotidis, Panayiotis; de Almeida, Antonio Medina; Mayer, Jiri; Hjorth Hansen, Henrik; Janssen, Jeroen; Mustjoki, Satu; Martinez Lopez, Joaquin; Vestergaard, Hanne; Ehrencrona, Hans; Kairisto, Veli; Dulucq, Stephanie; Machova, Katerina; Nicolini, Franck E.; Hofmann, Wolf Karsten; Guilhot, Joelle; Saussele, Susanne; Pfirrmann, Markus;
PUBLICAÇÃO: 2021, FONTE: BLOOD, VOLUME: 138
AUTORES: Mahon, Francois Xavier; Richter, Johan; Hochhaus, Andreas; Panayiotidis, Panayiotis; de Almeida, Antonio Medina; Mayer, Jiri; Hjorth Hansen, Henrik; Janssen, Jeroen; Mustjoki, Satu; Martinez Lopez, Joaquin; Vestergaard, Hanne; Ehrencrona, Hans; Kairisto, Veli; Dulucq, Stephanie; Machova, Katerina; Nicolini, Franck E.; Hofmann, Wolf Karsten; Guilhot, Joelle; Saussele, Susanne; Pfirrmann, Markus;
PUBLICAÇÃO: 2021, FONTE: BLOOD, VOLUME: 138
INDEXADO EM: 
WOS
WOS2
TÃTULO: Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-alpha Monotherapy Full Text
AUTORES: Mette Ilander; Anna Kreutzman; Peter Rohon; Teresa Melo; Edgar Faber; Kimmo Porkka; Jukka Vakkila; Satu Mustjoki;
PUBLICAÇÃO: 2014, FONTE: PLOS ONE, VOLUME: 9, NÚMERO: 1
AUTORES: Mette Ilander; Anna Kreutzman; Peter Rohon; Teresa Melo; Edgar Faber; Kimmo Porkka; Jukka Vakkila; Satu Mustjoki;
PUBLICAÇÃO: 2014, FONTE: PLOS ONE, VOLUME: 9, NÚMERO: 1
3
TÃTULO: Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy Full Text
AUTORES: Mustjoki, S; Auvinen, K; Kreutzman, A; Rousselot, P; Hernesniemi, S; Melo, T; Lahesmaa Korpinen, AM; Hautaniemi, S; Bouchet, S; Molimard, M; Smykla, R; Lee, FY; Vakkila, J; Jalkanen, S; Salmi, M; Porkka, K;
PUBLICAÇÃO: 2013, FONTE: LEUKEMIA, VOLUME: 27, NÚMERO: 4
AUTORES: Mustjoki, S; Auvinen, K; Kreutzman, A; Rousselot, P; Hernesniemi, S; Melo, T; Lahesmaa Korpinen, AM; Hautaniemi, S; Bouchet, S; Molimard, M; Smykla, R; Lee, FY; Vakkila, J; Jalkanen, S; Salmi, M; Porkka, K;
PUBLICAÇÃO: 2013, FONTE: LEUKEMIA, VOLUME: 27, NÚMERO: 4
4
TÃTULO: Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia Full Text
AUTORES: Anna Kreutzman; Taina Jaatinen; Dario Greco; Emmi Vakkila; Johan Richter; Marja Ekblom; Henrik Hjorth Hansen; Leif Stenke; Teresa Melo; Ron Paquette; Ruth Seggewiss Bernhardt; Agnes Guerci Bresler; Alexis Talbot; Jean Michel Cayuela; Francois Xavier Mahon; Kimmo Porkka; Jeff Lipton; Jukka Partanen; Philippe Rousselot; Satu Mustjoki;
PUBLICAÇÃO: 2012, FONTE: EXPERIMENTAL HEMATOLOGY, VOLUME: 40, NÚMERO: 11
AUTORES: Anna Kreutzman; Taina Jaatinen; Dario Greco; Emmi Vakkila; Johan Richter; Marja Ekblom; Henrik Hjorth Hansen; Leif Stenke; Teresa Melo; Ron Paquette; Ruth Seggewiss Bernhardt; Agnes Guerci Bresler; Alexis Talbot; Jean Michel Cayuela; Francois Xavier Mahon; Kimmo Porkka; Jeff Lipton; Jukka Partanen; Philippe Rousselot; Satu Mustjoki;
PUBLICAÇÃO: 2012, FONTE: EXPERIMENTAL HEMATOLOGY, VOLUME: 40, NÚMERO: 11
5
TÃTULO: Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated With Prolonged Therapy Responses In Advanced Leukemia.
AUTORES: Satu Mustjoki; Philippe Rousselot; Sari Jalkanen; Anna Kreutzman; Teresa Melo; Anna Maria Lahesmaa; Sampsa Hautaniemi; Mathieu Molimard; Richard Smykla; Francis Lee; Jukka Vakkila; Kimmo Porkka;
PUBLICAÇÃO: 2010, FONTE: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) in BLOOD, VOLUME: 116, NÚMERO: 21
AUTORES: Satu Mustjoki; Philippe Rousselot; Sari Jalkanen; Anna Kreutzman; Teresa Melo; Anna Maria Lahesmaa; Sampsa Hautaniemi; Mathieu Molimard; Richard Smykla; Francis Lee; Jukka Vakkila; Kimmo Porkka;
PUBLICAÇÃO: 2010, FONTE: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) in BLOOD, VOLUME: 116, NÚMERO: 21
INDEXADO EM: WOS
WOS